September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Wolfgang Miesbach: How Can the Sustainable Funding of Transformative Gene Therapies Be Ensured?

Wolfgang Miesbach/LinkedIn

Apr 28, 2026, 05:28

Wolfgang Miesbach: How Can the Sustainable Funding of Transformative Gene Therapies Be Ensured?

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

”Approved Gene Therapy. For Free. In 2026.

Regeneron’s Otarmeni (lunsotogene parvec‑cwha) – the first FDA‑approved gene therapy for genetic hearing loss – will be provided at no cost to clinically eligible patients in the United States.

Under a ‘Most Favored Nation’ (MFN)–style agreement with the U.S. government, linking U.S. prices to the lowest levels observed in comparable high‑income countries, Regeneron has committed to:

Providing Otarmeni at no cost to eligible U.S. patients (with treatment logistics and administration costs covered through established payer mechanisms).
Aligning Medicaid pricing – as well as future U.S. launch prices for selected medicines – with international benchmark levels.
Medicaid is the U.S. public insurance program covering tens of millions of individuals, including low‑income populations, children, people with disabilities, and older adults.
Expanding U.S.-based manufacturing and repatriating foreign revenues within an ‘America‑first’ pricing framework.

One big question remains:

How can the sustainable funding of transformative gene therapies be ensured in a manner that is equitable for both patients and healthcare systems?”

Stay updated with Hemostasis Today.